| Line Item | 2024-09-30 | Y/Y |
|---|---|---|
| Revenue | $7.94B | +20.6% |
| Cost of Revenue | $3.27B | +19.1% |
| Gross Profit | $4.67B | +21.6% |
| R&D Expense | $107.0M | +1.9% |
| SG&A Expense | $980.0M | +25.6% |
| Operating Income | $3.53B | +20.8% |
| Pre-tax Income | $2.21B | +29.1% |
| Income Tax | $500.0M | +19.9% |
| Net Income | $1.71B |
| Line Item | 2024-09-30 | Y/Y |
|---|---|---|
| Cash & Equivalents | $6.26B | +80.3% |
| Accounts Receivable | $1.38B | +12.3% |
| Inventory | $1.88B | +16.1% |
| Current Assets | $10.03B | +48.8% |
| Total Assets | $25.59B | +28.1% |
| Current Liabilities | $6.34B | +301.5% |
| Long-term Debt | $24.39B | +25.7% |
| Line Item | 2024-09-30 | Y/Y |
|---|---|---|
| Operating Cash Flow | $2.04B | +48.7% |
| Capital Expenditures | $165.0M | +18.7% |
| Investing Cash Flow | -$2.44B | -171.2% |
| Financing Cash Flow | $3.17B | — |
| Free Cash Flow | $1.88B | +52.1% |
| +32.0% |
| EPS (Basic) | $25.62 | +16.3% |
| EPS (Diluted) | $25.62 | +16.3% |
| Total Liabilities |
| $31.87B |
| +45.2% |
| Stockholders' Equity | -$6.29B | -217.0% |